Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Response Biomedical

This article was originally published in The Gray Sheet

Executive Summary

Rapid, on-site anthrax detection system based on the firm's RAMP technology is launched May 29. Intended for use by emergency responders, the environmental test can distinguish "between a hoax and a potentially infectious dose" in under 15 minutes, the firm claims. Vancouver-based Response hopes to place several hundred of the $10,000 systems by year-end, estimating a $500 mil. U.S. anthrax detection market within two years. The firm is in the process of signing co-marketing and distribution agreements. Separately, Response plans 510(k) submissions for CK-MB and troponin 1 analyte cardiac marker tests by the end of 2002. The RAMP reader was cleared in January for general clinical use along with a myoglobin cardiac marker test...

You may also be interested in...

Anthrax tests

U.S. Office of Science and Technology's July 19 recommendation against rapid anthrax field test use did not include Response Biomedical's RAMP even though the firm's competitors were included under the scope of the document, the firm claims. The test was commercially launched in May (1"The Gray Sheet" June 3, 2002, In Brief)...

EWG Study Suggests More Than One In 10 Talc-Based Cosmetics Contain Asbestos

The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts